Proactive Investors - Run By Investors For Investors

Imugene Limited releases new clinical data for HER-Vaxx cancer vaccine study

Imugene Limited (ASX:IMU) chief executive officer Leslie Chong updates Proactive Investors on new clinical data from the Phase 1b study of its HER-Vaxx cancer vaccine after presenting at the European Society for Medical Oncology World Congress on gastrointestinal cancer in Spain over the weekend.

The data shows the cancer fighting antibody and clinical response rates continue to be positive in patients receiving the optimal biological dose of the vaccine.

Imugene’s HER-Vax is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER-2/neu receptor such as gastric, breast, ovarian, lung and pancreatic cancers.

Chong said the latest presentation for the vaccine further reinforced ongoing interest among the international oncology community in Imugene’s potentially revolutionary B-cell platform cancer vaccine and clinical development.

 
Meet White Rock Minerals Ltd and Meteoric Resources NL at our event, Melbourne , 27 August 2019. Register here »
View full IMU profile View Profile

Imugene Ltd Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use